Monte Carlo calculation of the maximum therapeutic gain of tumor antivascular alpha therapy

Medical Physics

Volumn 39, Issue 3, 2012, Pages 1282-1288

  Huang, Chen Yu ^a   Oborn, Bradley M ^b,c   Guatelli, Susanna ^c   Allen, Barry J ^a  

^a UNIVERSITY OF NEW SOUTH WALES   (Australia)

^b Illawarra Cancer Care Centre   (Australia)

^c UNIVERSITY OF WOLLONGONG   (Australia)

Author keywords

endothelial cell; Geant4; microdosimetry; Monte Carlo; tumor antivascular alpha therapy

Indexed keywords

ALPHA PARTICLES; CAPILLARITY; CYTOLOGY; DERMATOLOGY; DISEASES; ENDOTHELIAL CELLS; ENERGY TRANSFER; MICROCIRCULATION; MONTE CARLO METHODS; ONCOLOGY; PROBABILITY DISTRIBUTIONS; SAFETY TESTING;

ANTIVASCULAR; GEANT4; METASTATIC MELANOMA LESIONS; MICRO-DOSIMETRY; MONTE CARLO CALCULATION; NON-UNIFORM DISTRIBUTION; SOURCE DISTRIBUTION; THERAPEUTIC EFFICACY;

TUMORS;

EID: 84863272302     PISSN: 00942405     EISSN: None     Source Type: Journal    
DOI: 10.1118/1.3681010     Document Type: Article

References (44)

1. C. Raja, Interim analysis of toxicity and response in phase 1 trial of systemic targeted alpha therapy for metastatic melanoma., Cancer Biol. Ther. 6, 846-852 (2007). 10.4161/cbt.6.6.4089
2. B. J. Allen, C. Raja, S. Rizvi, E. Y. Song, and P. Graham, Tumour anti-vascular alpha therapy: A mechanism for the regression of solid tumours in metastatic cancer., Phys. Med. Biol. 52, L15-L19 (2007). 10.1088/0031-9155/52/ 13/L01
3. H. Hashizume, Openings between defective endothelial cells explain tumor vessel leakiness., Am. J. Pathol. 156, 1363-1380 (2000). 10.1016/S0002-9440(10) 65006-7
4. S. Sofou, Radionuclide carriers for targeting of cancer., Int. J. Nanomed. 3, 181-199 (2008). 10.2147/IJN.S2736
5. R. Macklis, Radioimmunotherapy with alpha-particle-emitting immunoconjugates., Science 240, 1024-1026 (1988). 10.1126/science.2897133
6. J. L. Humm, J. C. Roeske, D. R. Fisher, and G. T. Chen, Microdosimetric concepts in radioimmunotherapy., Med. Phys. 20, 535-541 (1993). 10.1118/1.597049
7. R. F. Hobbs, A model of cellular dosimetry for macroscopic tumors in radiopharmaceutical therapy., Med. Phys. 38, 2892-2903 (2011). 10.1118/1.3576051
8. A. B. Rosenfeld, Simultaneous macro and micro dosimetry with MOSFETs., IEEE Trans. Nucl. Sci. 43, 2693-2700 (1996). 10.1109/23.556855
9. P. D. Bradley and A. B. Rosenfeld, Tissue equivalence correction for silicon microdosimetry detectors in boron neutron capture therapy., Med. Phys. 25, 2220-2225 (1998). 10.1118/1.598421
10. P. D. Bradley, A. B. Rosenfeld, B. Allen, J. Coderre, and J. Capala, Performance of silicon microdosimetry detectors in boron neutron capture therapy., Radiat. Res. 151, 235-243 (1999). 10.2307/3579934
11. T. G. Stinchcomb and J. C. Roeske, Analytic microdosimetry for radioimmunotherapeutic alpha emitters., Med. Phys. 19, 1385-1393 (1992). 10.1118/1.596770
12. J. L. Humm and L. M. Chin, A model of cell inactivation by alpha-particle internal emitters., Radiat. Res. 134, 143-150 (1993). 10.2307/3578453
13. J. C. Roeske and T. G. Stinchcomb, Dosimetric framework for therapeutic alpha-particle emitters., J. Nucl. Med. 38, 1923-1929 (1997).
14. S. J. Kennel, R. Boll, M. Stabin, H. M. Schuller, and S. Mirzadeh, Radioimmunotherapy of micrometastases in lung with vascular targeted 213Bi., Br. J. Cancer 80, 175-184 (1999). 10.1038/sj.bjc.6690337
15. D. E. Charlton, The survival of monolayers of cells growing in clusters irradiated by 211At appended to the cell surfaces., Radiat. Res. 151, 750-753 (1999). 10.2307/3580215
16. Y. Kvinnsland, T. Stokke, and E. Aurlien, Radioimmunotherapy with alpha-particle emitters: Microdosimetry of cells with a heterogeneous antigen expression and with various diameters of cells and nuclei., Radiat. Res. 155, 288-296 (2001). 10.1667/0033-7587(2001)155[0288:RWAPEM]2.0.CO;2
17. S. Incerti, H. Seznec, M. Simon, P. Barberet, C. Habchi, and P. Moretto, Monte Carlo dosimetry for targeted irradiation of individual cells using a microbeam facility., Radiat. Prot. Dosimet. 133, 2-11 (2009). 10.1093/rpd/ncp003
18. D. E. Charlton and B. J. Allen, Monte Carlo calculations of ion passages through brain endothelial nuclei during boron neutron capture therapy., Int. J. Radiat. Biol. 64, 739-747 (1993). 10.1080/09553009314551991
19. X. P. Zhu, M. R. Palmer, G. M. Makrigiorgos, and A. I. Kassis, Solid-tumor radionuclide therapy dosimetry: New paradigms in view of tumor microenvironment and angiogenesis., Med. Phys. 37, 2974-2984 (2010). 10.1118/1.3431999
20. G. Akabani, R. E. McLendon, D. D. Bigner, and M. R. Zalutsky, Vascular targeted endoradiotherapy of tumors using alpha-particle-emitting compounds: Theoretical analysis., Int. J. Radiat. Oncol., Biol., Phys. 54, 1259-1275 (2002). 10.1016/S0360-3016(02)03794-X
21. J. Allison, Geant4 developments and applications., IEEE Trans. Nucl. Sci. 53, 270-278 (2006). 10.1109/TNS.2006.869826
22. M. U. Bug, Effect of a magnetic field on the track structure of low-energy electrons: A Monte Carlo study., Eur. Phys. J. D 60, 85-92 (2010). 10.1140/epjd/e2010-00145-1
23. A. A. Maximow and W. Bloom, A Textbook of Histology (WB Saunders Company, Philadelphia and London, 1957).
24. R. M. Berne and M. N. Levy, Cardiovascular Physiology, 5 ed. (St Louis, Mosby, 1986).
25. S. Deguchi, K. Maeda, T. Ohashi, and M. Sato, Flow-induced hardening of endothelial nucleus as an intracellular stress-bearing organelle., J. Biomech. 38, 1751-1759 (2005). 10.1016/j.jbiomech.2005.06.003
26. S. Chauvie, Geant4 physics processes for microdosimetry simulation: Design foundation and implementation of the first set of models., IEEE Trans. Nucl. Sci. 54, 2619-2628 (2007). 10.1109/TNS.2007.910425
27. S. Incerti, Comparison of GEANT4 very low energy cross section models with experimental data in water., Med. Phys. 37, 4692-4708 (2010). 10.1118/1.3476457
28. J. C. Roeske and T. G. Stinchcomb, The use of microdosimetric moments in evaluating cell survival for therapeutic alpha-particle emitters., Radiat. Res. 151, 31-38 (1999). 10.2307/3579744
29. A. I. Kassis, F. Fayad, B. M. Kinsey, K. S. Sastry, R. A. Taube, and S. J. Adelstein, Radiotoxicity of 125I in mammalian cells., Radiat. Res. 111, 305-318 (1987). 10.2307/3576987
30. G. Sgouros, MIRD Pamphlet No. 22 (Abridged): Radiobiology and Dosimetry of a-Particle Emitters for Targeted Radionuclide Therapy., J. Nucl. Med. 51, 311-328 (2010). 10.2967/jnumed.108.058651
31. J. C. Roeske and T. G. Stinchcomb, The average number of alpha-particle hits to the cell nucleus required to eradicate a tumour cell population., Phys. Med. Biol. 51, N179-186 (2006). 10.1088/0031-9155/51/9/N02
32. B. J. Allen, Clinical trials of targeted alpha therapy for cancer., Rev. Recent Clin. Trials 3, 185-191 (2008). 10.2174/157488708785700339
33. C. Starr and R. Taggart, Biology: The Unity and Diversity of Life, 7 ed. (Wadsworth Publishing Company, California, 1995).
34. B. J. Allen, S. M. Rizvi, and Z. Tian, Preclinical targeted alpha therapy for subcutaneous melanoma., Melanoma Res. 11, 175-182 (2001). 10.1097/00008390-200104000-00013
35. T. R. Shockley, K. Lin, J. A. Nagy, R. G. Tompkins, M. L. Yarmush, and H. F. Dvorak, Spatial distribution of tumor-specific monoclonal antibodies in human melanoma xenografts., Cancer Res. 52, 367-376 (1992).
36. H. M. Shepard, Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic., J. Clin. Immunol. 11, 117-127 (1991). 10.1007/BF00918679
37. M. R. Dreher, W. G. Liu, C. R. Michelich, M. W. Dewhirst, F. Yuan, and A. Chilkoti, Tumor vascular permeability, accumulation, and penetration of macromolecular drug carriers., J. Natl. Cancer Inst. 98, 335-344 (2006). 10.1093/jnci/djj070
38. D. E. Charlton and R. Sephton, A relationship between microdosimetric spectra and cell survival for high-LET irradiation., Int. J. Radiat. Biol. 59, 447-457 (1991). 10.1080/09553009114550401
39. M. R. Zalutsky and O. R. Pozzi, Radioimmunotherapy with alpha-particle emitting radionuclides., Q. J. Nucl. Med. Mol. Imaging 48, 289-296 (2004).
40. D. E. Charlton and B. J. Allen, Dose sparing of capillary endothelial cells for BSH and BPA: A model for capillary truncation., Presented at the Sixth International Symposium on Neutron Capture Therapy for Cancer, Japan, 1994 (1996).
41. W. Wilkins, Expectancy of therapeutic gain: An empirical and conceptual critique., J. Cons. Clin. Psychol. 40, 69-77 (1973). 10.1037/h0034056
42. R. K. Jain, Delivery of novel therapeutic agents in tumors: physiological barriers and strategies., J. Natl. Cancer Inst. 81, 570-576 (1989). 10.1093/jnci/81.8.570
43. G. M. Thurber, M. M. Schmidt, and K. D. Wittrup, Antibody tumor penetration: Transport opposed by systemic and antigen-mediated clearance., Adv. Drug Delivery Rev. 60, 1421-1434 (2008). 10.1016/j.addr.2008.04.012
44. C.-Y. Huang, M. H. Pourgholami and B. J. Allen, Optimizing radioimmunoconjugate delivery in the treatment of solid tumor., Cancer Treat. Rev. (in press).